The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HF
Dewan P, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Lindholm D, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HF. European Heart Journal 2020, 41: ehaa946.0932. DOI: 10.1093/ehjci/ehaa946.0932.Peer-Reviewed Original ResearchChronic obstructive pulmonary diseaseEffect of dapagliflozinPrimary composite outcomeDAPA-HFHeart failureCV deathPlacebo groupComposite outcomeHazard ratioSodium-glucose cotransporter 2 inhibitorsAdditional effective therapiesReduced ejection fractionCotransporter 2 inhibitorsObstructive pulmonary diseaseCardiovascular deathDapagliflozin groupImportant comorbidityEjection fractionPrimary outcomePulmonary diseaseHF eventsSuboptimal treatmentWorse outcomesEffective therapyReduced risk